Dermatology

Researchers conducted a narrative review to explore the possibility of integrating social perspectives and aspects into dermatological care and research.

The review explored the “emerging” term gut-skin axis and aimed to decipher the bidirectional signaling of the skin and gastrointestinal tract during homeostatic and disease states.

PP405 targets the primary biological pathway that controls the natural hair growth cycle, separating it from existing therapies.

Researchers conducted a systematic review to summarize research that has addressed social media’s impact on skin health promotion activities.

Deucravacitinib demonstrated a statistically significant inhibition of radiographic progression compared to placebo.

Using the “Psoriasis and Beyond” survey design, researchers addressed patients’ awareness of psoriatic diseases and their associated comorbidities.

Researchers aimed to understand the treatment goals and preferences of young patients with atopic dermatitis and their caregivers.

ASC40 blocks facial sebum production by inhibiting de novo lipogenesis in sebocytes and inflammation by decreasing cytokine secretion and Th17 differentiation.

Researchers explored the current evidence regarding women’s reactions to biological therapies for treating atopic dermatitis during pregnancy.

The supplemental new drug application for roflumilast (Zoryve) is approved for adult and pediatric patients 12 years and older.

Through a comprehensive review and meta-analysis, researchers identified the correlation between atopic dermatitis and dementia.

Researchers conduct a scoping review to update and determine what the best available options are for treating patients with skin-picking disorder.

In children aged 5 to 17 with skin disorders, researchers explore the risk of developing psychosocial comorbidities, sleep disturbances, and common related symptoms.

Researchers conducted a clinical review detailing the intersection of dermatology and suicide, explaining why skin conditions lead to increased risk of poor mental health.

In a phase 3 study, 57% of patients treated with icotrokinra achieved an Investigator's Global Assessment score of 1 or 0 and a grade 2 or more improvement at week 16.

The therapy achieved positive results during a phase 2b trial on the primary endpoint of percent change in Eczema Area and Severity Index (EASI) score.

The therapy is currently under FDA review and has a PDUFA action date of May 22, 2025.

Researchers conducted a review of adherence behaviors for patients with dermatological diseases and provided an update on management strategies.

Results are from an open-label extension of a phase 3 trial assessing the pharmacokinetics, efficacy, safety, and immunogenicity of adalimumab-aaty and its reference formulation Humira.

Researchers conducted an observational cost analysis of dermatology drug savings between GoodRx and Mark Cuban Cost Plus Drug Company.

From 1990 to 2021, researchers explored the global burden of atopic dermatitis among older adults.

The approval is based on 2 phase 3 studies demonstrating reductions in itch severity and urticaria activity as a composite of itch and hives at 24 weeks.

Researchers conduct a review to understand the efficacy and safety of topical minocycline for the treatment of moderate to severe papulopustular rosacea.

The subgroup analysis shows adolescents treated with the drug once daily had higher rates of clear or almost clear skin compared to patients receiving the placebo.

Over 20 years since skin of color dermatology was introduced, researchers explored advancements and what is yet to come in the future.

The FDA approved adalimumab-aaty in May 2023 for 8 indications, including rheumatoid arthritis, psoriatic arthritis, Crohn disease, ulcerative colitis, and plaque psoriasis.

Researchers explored TikTok’s role in the dissemination of information regarding isotretinoin and its users.

In a comprehensive review, researchers aimed to explore seasonality, environmental factors, and the genetic and epigenetic mechanisms of patients living with psoriasis vulgaris.

In a review of skin inflammation’s link to food allergen sensitivity, researchers explored how patients with atopic dermatitis may be more susceptible to the development of food allergies.

Patients treated with the therapy showed significantly less progression of structural damage compared to patients who received placebo at week 24.